NO970108L - Konjugat mellom et modifisert superantigen og en målsökende forbindelse samt anvendelse av konjugatet - Google Patents

Konjugat mellom et modifisert superantigen og en målsökende forbindelse samt anvendelse av konjugatet

Info

Publication number
NO970108L
NO970108L NO970108A NO970108A NO970108L NO 970108 L NO970108 L NO 970108L NO 970108 A NO970108 A NO 970108A NO 970108 A NO970108 A NO 970108A NO 970108 L NO970108 L NO 970108L
Authority
NO
Norway
Prior art keywords
conjugate
peptide
targeting compound
modified superantigen
modified
Prior art date
Application number
NO970108A
Other languages
English (en)
Other versions
NO970108D0 (no
NO320151B1 (no
Inventor
Lars Abrahmsen
Per Bjoerk
Mikael Dohlsten
Terje Kalland
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of NO970108D0 publication Critical patent/NO970108D0/no
Publication of NO970108L publication Critical patent/NO970108L/no
Publication of NO320151B1 publication Critical patent/NO320151B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19970108A 1994-07-11 1997-01-10 Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre NO320151B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
PCT/SE1995/000681 WO1996001650A1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

Publications (3)

Publication Number Publication Date
NO970108D0 NO970108D0 (no) 1997-01-10
NO970108L true NO970108L (no) 1997-02-20
NO320151B1 NO320151B1 (no) 2005-10-31

Family

ID=20394684

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19970108A NO320151B1 (no) 1994-07-11 1997-01-10 Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre

Country Status (26)

Country Link
US (3) US7226601B1 (no)
EP (1) EP0766566B1 (no)
JP (1) JP4175489B2 (no)
KR (1) KR100377506B1 (no)
CN (1) CN1089606C (no)
AT (1) ATE200626T1 (no)
AU (1) AU699147B2 (no)
CA (1) CA2194673C (no)
DE (1) DE69520739T2 (no)
DK (1) DK0766566T3 (no)
ES (1) ES2158950T3 (no)
FI (1) FI118150B (no)
GR (1) GR3036187T3 (no)
HU (1) HU221254B1 (no)
IL (1) IL114445A (no)
MY (1) MY112916A (no)
NO (1) NO320151B1 (no)
NZ (1) NZ289951A (no)
PL (1) PL180747B1 (no)
PT (1) PT766566E (no)
RU (1) RU2183215C2 (no)
SE (1) SE9402430L (no)
TW (1) TW413636B (no)
UA (1) UA73067C2 (no)
WO (1) WO1996001650A1 (no)
ZA (1) ZA955746B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
DE19827837A1 (de) * 1998-06-23 1999-12-30 Ernst Gleichmann Universell an Haupthistokompatibilitätskomplexmoleküle der Klasse II bindende Peptide zur prädiktiven Testung, Diagnostik, Prophylaxe und Therapie von Sensibilisierungen gegen Chemikalen
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ519371A (en) 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1812574A2 (en) * 2004-11-18 2007-08-01 Avidex Limited Soluble bifunctional proteins
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
WO2014025199A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
KR20250071286A (ko) 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
WO2020013803A1 (en) * 2018-07-09 2020-01-16 Synthis, Llc Antibody-alk5 inhibitor conjugates and their uses
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627644A (en) 1968-03-01 1971-12-14 Hajime Okamoto Process for the cultivation of hemolytic streptococci
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4268434A (en) 1979-01-09 1981-05-19 Higerd Thomas B Immunosuppressive extracellular product from oral bacteria
SU1304736A3 (ru) * 1981-04-14 1987-04-15 Др.Мадаус Унд Ко (Фирма) Способ получени противоопухолевого средства
US5091091A (en) 1981-11-06 1992-02-25 Terman David S Protein A perfusion and post perfusion drug infusion
US4699783A (en) 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4681870A (en) 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
IT1192014B (it) 1986-06-27 1988-03-31 Rubinetterie Mariani Spa Becco di erogazione per lavabo o simile apparecchio idraulico con comando del salterello
US4980160A (en) 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
EP0355047B1 (en) 1988-07-22 1993-06-30 Imre Corporation Purified protein a compositions and methods for their preparation
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
EP1129717B2 (en) 1990-01-17 2013-03-06 TERMAN, David S. Use of homologues of staphylococcal enterotoxins for cancer treatment
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
JPH08500328A (ja) 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
AU699147B2 (en) 1998-11-26
EP0766566A1 (en) 1997-04-09
CA2194673C (en) 2009-08-04
MY112916A (en) 2001-10-31
ATE200626T1 (de) 2001-05-15
RU2183215C2 (ru) 2002-06-10
UA73067C2 (en) 2005-06-15
IL114445A (en) 1999-09-22
FI970100A0 (fi) 1997-01-10
HUT77257A (hu) 1998-03-02
AU2994095A (en) 1996-02-09
PL318162A1 (en) 1997-05-26
WO1996001650A1 (en) 1996-01-25
JP4175489B2 (ja) 2008-11-05
IL114445A0 (en) 1995-11-27
ZA955746B (en) 1996-02-20
DE69520739T2 (de) 2001-09-20
EP0766566B1 (en) 2001-04-18
US20060062795A1 (en) 2006-03-23
HU221254B1 (en) 2002-09-28
US7226601B1 (en) 2007-06-05
US20050260215A1 (en) 2005-11-24
CN1152877A (zh) 1997-06-25
PL180747B1 (pl) 2001-04-30
ES2158950T3 (es) 2001-09-16
GR3036187T3 (en) 2001-10-31
NO970108D0 (no) 1997-01-10
FI970100L (fi) 1997-01-10
SE9402430L (sv) 1996-01-12
DE69520739D1 (de) 2001-05-23
JPH11500407A (ja) 1999-01-12
CA2194673A1 (en) 1996-01-25
NO320151B1 (no) 2005-10-31
PT766566E (pt) 2001-09-28
KR100377506B1 (ko) 2003-06-11
SE9402430D0 (sv) 1994-07-11
NZ289951A (en) 1998-12-23
CN1089606C (zh) 2002-08-28
DK0766566T3 (da) 2001-08-13
FI118150B (fi) 2007-07-31
TW413636B (en) 2000-12-01
HK1012226A1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
NO970108D0 (no) Konjugat mellom et modifisert superantigen og en målsökende forbindelse samt anvendelse av konjugaten
Dolimbek et al. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
Galloway et al. Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
RU97102113A (ru) Конъюгат между модифицированным суперантигеном и направленным к мишени соединением и применение конъюгата
EP0820469A4 (en) IDENTIFICATION, CLEANING AND USE OF LECZYMS AND CARBOHYDRATE LIGANDS
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
US4902495A (en) IgE Fc directed delivery system
Brunda et al. Heterogeneity of binding of human IgA subclasses to protein A
AU641736B2 (en) Delivery of agents
Givner et al. Type III group B Streptococcus: functional interaction with IgG subclass antibodies
Hamilton et al. Humoral immune responses in Peyronie’s disease patients receiving clostridial collagenase therapy
DuPont et al. Suppression of passive transfer acute experimental myasthenia by F (ab′) 2 fragments
ES480624A1 (es) Un metodo para producir antisueros o anticuerpos contra una glicoproteina asociada con el cancer.
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper
RU2020137888A (ru) Человеческие антитела, связывающиеся с ror2
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
AU3633695A (en) Use of antibodies to block the effects of gram-positive bacteria and mycobacteria

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees